托吡酯联合用药治疗婴幼儿重症癫癎

目的 评价托吡酯(TPM)联合用药治疗婴幼儿重症癫癎的疗效及安全性。方法 对12例重症癫癎婴幼儿(年龄4~19个月)采用TPM联合用药治疗。TPM应用是根据发作形式和频率在原来一个或多个抗癫癎药物的基础上进行联合用药治疗。结果 TPM的起始剂量0.5~1.0mg／(kg·d),加量1次／1~2周,剂量为0.5~1.0 mg／(kg·d),目标剂量为4~10 mg／(kg·d)。TPM治疗时间平均为6.2个月,总有效率75％,无效率25％,完全控制为50％。临床观察局灶性发作疗效明显优于全面性强直-阵挛发作。TPM不良反应较轻,仅3例出现睡眠减少、发热及语言减少。结论 TPM联合用药治疗婴儿重症癫癎有效率较高,是一种安全性好、不良反应轻的治疗方法。     

奥卡西平治疗儿童癫(癎)的临床随访研究

目的 探讨奥卡西平治疗儿童癫(癎)部分性发作及难治性癫(癎)的临床疗效和安全性.方法 2005-2006年上海新华医院小儿神经科收治癫(癎)患者52例,其中新诊断和未经治疗癫(癎)部分性发作患者37例为单药治疗组;15例为既往经2种以上抗癫(癎)药正规治疗,发作仍未控制者为添加治疗组.起始剂量5～10 mg/(kg·d),每日2次口服,每5～7 d,增加5～10 mg/(kg·d),目标剂量20～40 mg/(kg·d).观察期为6个月至2年,进行自身对照开放性研究,观察其疗效、安全性及依从性,分析剂量与不同年龄及疗效的关系.结果 单药治疗组有效率为(控制+显效+有效)89.19%,控制率为67,57%,退出率为2.70%;难治组有效率为46.67%,控制率为13.33%,退出率为26.67%.共5例退出,1例因皮疹退出,4例因发作未能控制而退出.小于4岁患儿的平均剂量较年长儿显著增高(P＜0.05).发作减少50%以上的病例的平均剂量较发作减少50%以下者显著增高(P＜0.05).21.15%的病例发生不良反应,包括困倦、头晕、乏力、皮疹等,无低钠血症发生.结论 奥卡西平治疗儿童部分性癫(癎)疗效显著,对难治性癫(癎)的也有一定的疗效,临床应用依从性良好,不良反应较少,安全性好.     

奥卡西平联合其他抗癫(癎)药治疗儿童癫(癎)的疗效及安全性

目的 探讨奥卡西平(OXC)联合用药治疗儿童癫(癎)的疗效、剂量及药物安全性.方法 收集在本院神经内科门诊就诊的41例癫(癎)患儿.男23例,女18例;就诊年龄6个月～l5岁,平均7.70岁;病程15 d-5 a,平均9个月;随访时间6个月～6a,平均2a6个月.简单局限性发作(SPS)3例,复杂局限性发作(CPS)8例,局限性发作继发全面性发作(sGTCS) 14例,SPS和sGTCS 2种类型均有12例,CPS和sGTCS均有4例.根据应用OXC的先后顺序分为A组与B组:A组为开始应用一种非OXC抗癫(癎)药治疗,因疗效不好,在原用药剂量不变的情况下加用OXC;B组为首选OXC治疗后因仍有发作加用其他抗癫(癎)药物.回顾性分析41例OXC联合用药治疗癫(癎)患儿的临床资料,评估其疗效、药物不良反应及患儿的耐受性.结果 A组29例,经OXC添加治疗完全控制发作者占48.3％,发作频率减少≥50％(即总有效率)82.7％;OXC所用剂量为(26.70±6.75) ng·kg-1·d-1.其中12例成功转换为OXC单药治疗,10例单药治疗无发作.B组OXC加小剂量硝西泮药物组合治疗,发作频率减少均≥50％,疗效最高.对发作类型比较,OXC对各种局限性发作类型发作频率减少均≥50％.本研究中8例(19.5％)出现OXC相关药物不良反应,依次为困倦3例,皮疹2例,视物不清、无症状血钠减低和膝关节痛各l例,分别经缓慢加量、略减量或未进行任何处理,上述症状自行消失.结论 OXC联合用药治疗癫(癎)疗效高而稳定,耐药性小,安全性高,是适合于长期应用的新型高效抗癫(癎)药物之一.     

左乙拉西坦治疗儿童癫(癎)51例自身对照研究

目的 研究左乙拉西坦(Lev)作为添加治疗不同类型儿童癫(癎)的临床疗效和安全性.方法 采用前瞻性研究51例不同类型耐药性癫(癎)患儿(男37例,女14例;平均年龄8.7岁)使用Lev作为添加治疗(发作形式包括复杂局限性发作20例,局限性发作继发全面性发作4例,强直-阵挛发作10例,强直发作1例,肌阵挛发作6例,眼肌痉挛型2例,Lennox-Gastaut综合征2例,婴儿痉挛症4例,不能分类的癫(癎)性脑病2例),原抗癫(癎)药继续服用.Lev起始剂量为20 mg/(kg·d),分2次服用,每2周增加10 mg/(kg·d),维持剂量30～40 ms/(kg·d).以治疗前3个月的发病频率为基础,平均随访6.8个月,观察发作频率变化及不良反应.6例分别因无效、发作加重、不能耐受终止Lev治疗.采用SPSS 14.0软件比较癫(癎)患儿Lev治疗前后发作频率的差别.结果 有效13例,占25.5%;显效9例,占17.6%;无发作16例,占31.4%;无效8例,占15.7%;加重5例,占9.8%.Lev治疗前后发作频率改变有统计学意义(P<0.005).结论 Lev作为添加治疗对于儿童各型癫(癎)均有疗效,尤其对于复杂局限性发作、肌阵挛发作等具有较好治疗效果,且不良反应轻,是一种安全性好,疗效佳的抗癫(癎)新药.     

奥卡西平治疗儿童良性癫(癎)伴中央颞区棘波的临床观察

目的观察奥卡西平(OXC)治疗儿童良性癫癎伴中央颞区棘波(BECT)的疗效和安全性。方法用OXC治疗17例BECT患儿,分析单药治疗后1、2、4、6个月的疗效和不良反应。OXC起始剂量为5～10mg/(kg·d),每隔1周增加1次剂量5～10mg/(kg·d),维持剂量20～30mg/(kg·d)。结果本组总有效率为88.24%,服药6个月时累积控制率为70.59%,留存率为94.12%,均呈现较高比率。结论OXC治疗BECT的疗效明显,不良反应轻,安全性高。     

妥泰快速增量治疗婴幼儿期频繁发作癫癎

目的 观察妥泰快速增量法用于婴幼儿期频繁发作的癫癎治疗。方法 对43例年龄2个月17d～2岁的多种发作类型的婴幼儿期癫癎患儿,从1～2mg/(kg·d)起始,以每2～3d或3～7d快速增量,分别在1、2或3周达目标剂量或最大疗效,观察分析其疗效和不良反应。结果 均完成1～3周增量期。最大剂量2.2～10mg/(kg·d)[平均4.9±1.0mg/(kg·d)]。除3例治疗后4～8周中断外,观察时间均为3～9个月。1周后达最大剂量者19例(44.2％),2周或3周者分别17例(39.5％)或7例(16.3％)。26例为妥泰单药治疗。发作减少50％以上的总有效率为83.3％,其中51.2％发作完全控制。22/43例(51.2％)发生35人次不良反应,以食欲减退(9/22例)、嗜睡(7/12例)和体重减轻(6/22例)最常见,次为出汗减少和奖吵不安(各4/22例),汗少伴发热或轻泻(各2/22例),皮疹和睡眠减少(各1/22例)等。除1例因无汗伴发热和1例与卡马西平联用发生皮疹自行停药外,均继续用药,并在2～7周消失。结论 无论单药或联合用药,对频繁发作的婴儿期癫癎,采用快速增量法既不影响疗效,且安全可行。食欲减退和嗜睡是最常见的早期副作用。应根据病情需要和个体耐受力决定不同剂量和增量速度。考虑婴幼儿生理特性,应对快速加量者作更多临床和实验室监测。     

应用拉莫三嗪治疗不同类型癫(癎)130例

目的 探讨拉莫三嗪(LTG)单药及联合用药治疗不同类型癫(癎)发作的疗效.方法 选择疗程在6个月以上共130例不同发作类型的癫(癎)患儿,口服LTG单药或联合用药治疗,年龄5个月～17岁,进行开放性自身对照临床试验.1.单药组LTG初始量:≥12岁者25 mg·d-1,每周递增25 mg·d-1;＜12岁者0.5～2.0 mg·kg-1·d-1,每周递增0.5～2.0 mg·kg-1·d-1.2.联合组:原用丙戊酸钠、托吡酯、左乙拉西坦者,起始量:≥12岁者12.5 mg·d-1,每周递增12.5 mg·d-1; ＜12岁者0.15～0.30 mg·kg-1·d-1,每周递增0.3 mg·kg-1·d-1.原用苯巴比妥、卡马西平、奥卡西平者,起始量:≥12岁者50 mg·d-1,每周递增50 mg·d-1; ＜12岁者0.15～0.30 mg·kg-1·d-1,每周递增0.3 mg·kg-1·d-1.以上均4～8周达维持量.结果 130例中107例有效控制发作,总有效率达82.31%,其中62例完全控制发作;单药组和联合组疗效比较差异无统计学意义(P>0.05).出现不良反应14例,其中皮疹9例,嗜睡、头痛、头晕、食欲减少、烦躁各1例.结论 LTG是一种广谱、高效、安全的抗癫(癎)药物,无论单药或者联合用药治疗均有较好疗效.     

左乙拉西坦单药治疗小儿癫癎的疗效和安全性随访研究

目的：评价左乙拉西坦(LEV)单药治疗小儿癫癎的疗效和安全性。方法：对该院2007年3月至2008年3月LEV单药治疗的32例癫癎患儿进行开放性自身对照随访研究,起始量每日10 mg/kg,每1周增加上述剂量1次,3~4周增加至维持剂量每日20～60 mg/kg,平均剂量为每日35 mg/kg。结果：LEV 单药治疗32例,失访1例,其余随访均在3个月以上。 80.6%（25/31）患儿发作减少≥50%,70.9%（22/31）患儿无发作,16.1%（5/31）患儿因发作控制不满意或者加重而停药。不良反应包括情绪异常19.4%（6/31）,乏力6.5%（2/31）,嗜睡6.5%（2/31）,皮疹3.2%（1/31）。上述不良反应均为一过性,在1～4 周内自然消失或者减量后消失,未导致停药,未发现过敏以及血液、肝、肾功能异常等严重不良反应。结论：LEV用于癫癎患儿（包括<4岁的婴幼儿）的部分性发作及全身性发作的单药治疗,疗效肯定、安全性好,是一个很有希望的用于儿童单药治疗的广谱抗癫癎药。     

咪达唑仑持续静脉泵入治疗儿童癫(癎)持续状态的疗效观察

目的 观察咪达唑仑治疗儿童癫(癎)持续状态的疗效及不良反应.方法 将癫(癎)持续状态患儿按随机分配原则分为2组:研究组给予咪达唑仑0.3 mg/kg静注,15 min后若发作未能控制,以1～2 μg/(kg·min)持续静脉泵入,每15min增加1 μg/(kg·min),最大量20 μg/(kg·min).对照组给予安定0.3mg/kg静注,15 min后若发作未能控制,以5 μg(kg·min)持续静脉泵入.每15分钟增加.5 μg/(kg·min),最大量50 μg/(kg·min).结果 咪达唑仑组7例癫(癎)发作完全控制,1例在药量达20 μg/(kg·min)癫(癎)发作仍未控制,本组患儿控制癎痴持续状态的有效率为87.5%.安定组6例癫(癎)发作完全控制,1例在药量达50 μg/(kg·min)癫(癎)发作未控制,本组患儿控制癫(癎)持续状态的有效率为83.3%.两组控制惊厥疗效及控制惊厥药物起效时间的比较无显著性.安定组1例肌张力减低和1例呼吸抑制.咪达唑仑组未发现血压、心率、血氧饱和度和呼吸状态的变化.结论 咪达唑仑治疗癫(癎)持续状态起效快,效果好,不良反应小,可用于治疗癫(癎)持续状态.     

静脉注射人血丙种球蛋白与阿昔洛韦联合治疗单纯疱疹病毒性脑炎疗效观察

目的 探讨静脉注射人血丙种球蛋白(IVIG)与阿昔洛韦联合治疗儿童单纯疱疹病毒性脑炎(HSE)的疗效与安全性。方法 随机选取29例HSE患儿,分为IVIG加阿昔洛韦组和单用阿昔洛韦组,IVIG 400mg／(kg·d),静滴,连用4 d;阿昔洛韦15~30 mg／(kg·d),分3次静滴,连用10~14 d。结果 IVIG加阿昔洛韦组14例中9例(64.29％)治愈;而阿昔洛韦组15例中4例(26.67％)治愈,两组比较治愈率有显著差异(P<0.05)。治疗后IVIG加阿昔洛韦组退热时间[(1.7±1.2)d]及昏迷转清醒时间[(1.8±1.0)d]均较阿昔洛韦治疗组[分别为(3.2±1.5)d和(3.3±1.4)d]明显缩短(P<0.01,P<0.05)。惊厥缓解率IVIG加阿昔洛韦组(75.00％)明显高于阿昔洛韦组(33.33％)(P<0.05);惊厥持续状态治疗效果差,全身性抽搐继发癫癎者(9.10％)少,而局限性抽搐继发癫癎高达66.67％,两者比较具有极显著差异(P<0.01)。治疗中无1例发生不良反应。结论 静脉注射用IVIG与阿昔洛韦联合治疗HSE疗效明显优于单用阿昔洛韦,且安全性较高。惊厥类型是影响疗效及预后的重要因素。     

Clinical experiences with topiramate in children with intractable epilepsy.

At a tertial referral epilepsy centre 39 children were consecutively enrolled in an open add-on study with topiramate (TPM). All children had intractable epilepsy; the mean seizure frequency was 36 per month, and 31 children were treated with polypharmacy. All but five children were mentally retarded. The initial dose of TPM was 0.5-1 mg/kg daily, slowly titrated with 1-3 mg/kg daily every second week with an estimated target dose of 10 mg/kg daily. At latest follow-up 19 children continued on TPM, three (8%) were seizure-free, eight (21%) had a seizure reduction of more than 50% and eight (21%) improved their general condition. Mean follow-up was 13 months (range 9-36 months). Seizure reduction was seen in focal as well as generalized epilepsies. Adverse effects were reported in 21 cases (54%), weight loss and sedation being most frequent. The mean steady state dose in the children continuing on TPM was at latest follow-up: 14 mg/kg daily (< 5 years), 10 mg/kg daily (5-7 years), 5.8 mg/kg daily (8-17 years). The corresponding plasma level varied from 3 to 45 mumol/litre, and a significant correlation between the daily dose in mg/kg and the plasma level was found. Two patients with progressive myoclonus epilepsy are described separately; one had a dramatic general improvement. It is concluded that TPM seems to be a promising new broad-spectrum anti-epileptic drug, which is efficacious even in epilepsy syndromes, intractable to other new anti-epileptic drugs such as vigabatrin and lamotrigine.     

Topiramate for drug-resistant epilepsies.

Topiramate is a new anti-epileptic drug with proven efficacy against partial seizures in adults. A retrospective assessment of the use of topiramate in drug-resistant childhood epilepsy was undertaken. Thirty-four children (median age of 10 years; range 2-18 years) were treated for a median of 9 months (range 6-18 months). The starting dose was 0.25-2.0 mg/kg/day increasing to a maximum of 13 mg/kg/day. Generalized seizures occurred in 27 patients, partial seizures in 15 and infantile spasms in two. Epilepsies were localization-related in 15 patients and generalized in 18. One patient had severe myoclonic epilepsy in infancy. Two patients had Lennox-Gastaut syndrome, five (two currently and three previously) had West syndrome and one had epilepsy with myoclonic absences. Twenty patients had a substantial (> 50%) reduction in seizure frequency; two of whom became seizure-free. Two-patients had an increase in seizures. Efficacy was seen against simple and complex partial seizures, generalized tonic-clonic seizures (primarily generalized), atonic and tonic seizures, myoclonic seizures and infantile spasms. There was no response in the one patient with myoclonic absence seizures. Adverse effects were reported in nine patients; appetite suppression occurred in five patients, behaviour disturbances in three, somnolence in two and poor concentration in one patient. Topiramate is efficacious in a wide spectrum of childhood epilepsies and is well tolerated.     

Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy

BACKGROUND: Zonisamide is licensed in the EU and USA for the adjunctive treatment of partial-onset seizures in adults but there are few data about its use in children. AIMS: To assess the long-term safety and efficacy of zonisamide in children and adolescents. METHODS: Zonisamide-na?ve patients (n=109, aged 3-15 years, weight >or=12.5 kg) with a clinical diagnosis of epilepsy (>or=4 seizures/month, receiving 1-2 antiepileptic drugs [AEDs] daily) received zonisamide once or twice daily in an open-label trial. The starting dose was 1mg/kg/day, increased by 2 mg/kg/day every 1-2 weeks at the investigator's discretion to an initial maximum of 12 mg/kg/day. The occurrence of adverse events (AEs) was the primary safety measure. Efficacy was measured via the reductions in seizure frequency and via investigator- and carer-rated global assessment ratings. RESULTS: The mean dose received was 8.5 mg/kg/day. Of the 109 children, 52 (48%) completed 15 months' treatment. Treatment-related AEs, mostly mild-to-moderate in severity, were reported by 58 patients. Seven patients discontinued due to treatment-related AEs. Serious AEs (pancreatitis, decreased sweating, and vertigo) were reported by three patients. A significant (p=0.033) median reduction in 'all seizure' frequency of 2.60 seizures per week was observed. Additionally, a significant (p=0.029) median reduction of 1.80 seizures/week in 'complex partial' seizures was reported. Improvements in investigator- and carer-rated global assessments were noted. CONCLUSIONS: Zonisamide treatment was generally well tolerated and was associated with significant reductions in seizure frequency in this pediatric population with a variety of both partial and generalized medically refractory epilepsy syndromes.     

Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy

BackgroundLacosamide is effective and well-tolerated antiepileptic drug (AED) in both children and adults.AimThis multicentric, prospective study investigates the efficacy and safety of lacosamide adjunctive therapy in children aged less than four years presenting with refractory focal seizures.MethodsLacosamide was added to the baseline therapy at a starting dose of 1–2 mg/kg/day and titrated to the final dose, ranging from 7 to 15.5 mg/kg/day. Efficacy was evaluated after a three-month period of therapy. When possible, we compared the initial efficacy and the retention after a minimum of 12 months of lacosamide, with regard to loss of efficacy (defined as the return to the baseline seizure frequency).ResultsTwenty-four children were enrolled in the study. Mean age was 2.7 years. After a minimum three-month period of lacosamide add-on therapy, ten (42%) patients were responders (more than a 50% decrease in seizure frequency), of whom 4 (17%) became seizure free. Retention rate, after a minimum of 12 months of lacosamide, was evaluated in a group of 18 patients. In the latter group, eight patients (44%) were initial responders (three of whom seizure free). After 12 months of follow-up, four of them (22%) maintained the improvement, 2 (11%) of whom remained seizure free. A loss of efficacy was observed in 4 of the initial responders (50%). Adverse events were seen in 8 (33%) patients.ConclusionWe conclude that lacosamide is an effective and a well-tolerated antiepileptic drug in an etiologically wide range of focal seizures. Therefore, lacosamide might represent a possible therapeutic option in infants and young children affected by uncontrolled focal epilepsy.     

Topiramate as a new antiepileptic drug in epileptic children in Iran

Objective It is known that current antiepileptic drugs cannot control seizures in 20–30% of patients. The aim of this study was to evaluate the efficacy and safety of topiramate (TPM) as add-on therapy in intractable epileptic children in Iran. Methods As a quasi- experimental (before and after) study, 42 iranian children aged 1–15 years, 28 boys and 14 girls with refractory seizures seeking treatment were recruited to be subjects of this study. Results Type of seizures of those 42 epileptic children were as follows: L.G.S. (n=14), idiopathic epilepsy (n=8), symptomatic epilepsy (n=16) and progressive myoclonic epilepsy (n=4). At the end of three months of treatment in which topiramate was used concomitantly with previous AED, 17% became seizure free, 26% had more than 50% reduction of seizure frequency and 5% of them had increasing seizures. Therefore, the drug is statistically significant in seizures reduction. The efficacy of the drug was statistically significant in idiopathic and symptomatic epilepsy. The author’s did not notice any serious side effects such as: hematologic abnormality, hepatotoxicity and nephrotoxicity. Conclusion This study supports efficacy and safety of TPM in controlling of intractable epilepsy in children and indicates the drug should be considered as an add-on therapy in the management of refractory epileptic syndromes.     

Add-on levetiracetam in children and adolescents with refractory epilepsy: Results of an open-label multi-centre study

PURPOSE: To study the efficacy and tolerability of add-on levetiracetam in children and adolescents with refractory epilepsy. METHODS: In this prospective multi-centre, open-label, add-on study, 33 children aged 4-16 years (median 8.5 years) with epilepsy refractory to at least two antiepileptic drugs were treated with levetiracetam in addition to their present treatment regimen with a follow-up of 26 weeks. The starting dose of 10 mg/kg/day was increased with 2-week steps of 10 mg/kg/day, if necessary, up to a maximum dose of 60 mg/kg/day. RESULTS: Retention rate was 69.7% after 26 weeks on a median levetiracetam dosage of 22 mg/kg/day. Four children dropped-out because levetiracetam was ineffective, four because seizure frequency increased and/or seizures became more severe, and two because they developed aggressive behaviour. Compared to their baseline seizure frequency, 13 children (39.4%) had a >50% seizure reduction 12 weeks after initiation of levetiracetam, and 17 children (51.5%) at 26 weeks. At 26 weeks, nine children (27.3%) had been seizure-free for at least the last 4 weeks, terminal remission ranged from 0 to 187 days (mean 46 days). Levetiracetam was effective in both partial and primary generalized seizures, but had most effect in partial seizures. Most reported side effects were hyperactivity (48.5%), somnolence (36.4%), irritability (33.3%) and aggressive behaviour (27.3%). Severity of most side effects was mild. Five children had a serious adverse event, which all concerned hospital admissions that were not related to levetiracetam use. CONCLUSION: Levetiracetam proved to be an effective and well-tolerated add-on treatment in this group of children with refractory epilepsy.     

Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies

BackgroundStudies on the efficacy and tolerability of rufinamide in infants and young children are scarce. Here we report on an open, retrospective, and pragmatic study about safety and efficacy of rufinamide in children aged less than four years, in terms of seizures types and epilepsy syndromes.MethodsForty children (mean age 39.5 months; range 22–48) were enrolled in the study. The mean follow-up period was 12.2 months (range 5–21). Rufinamide was initiated at a mean age of 26.7 months (range 12–42). Final rufinamide mean dosage was 31.5 mg/kg/day if associated with valproic acid and 44.2 mg/kg/day if not.ResultsThe highest seizure reduction rate was observed in the epileptic spasms (46%) and drop attacks (42%) groups. Seizure reduction was also observed in tonic seizures (35%) and in the focal seizure (30%) groups. In terms of epilepsy syndrome, rufinamide was effective in Lennox–Gastaut syndrome. Results were very poor for those affected by Dravet's syndrome. Globally, responder rate was 27.5%, including two (5%) patients seizure-free. Adverse reactions occurred in 37.5% of children and were mainly represented by vomiting, drowsiness, irritability, and anorexia. Discontinuation rate due to treatment-emergent adverse events was 15%.ConclusionThe present study concludes that rufinamide may be a safe and effective drug for a broad range of seizures and epilepsy syndromes in infants and young children and represents a valid therapeutic option in this population.     

Efficacy of Pregabalin in Childhood Refractory Partial Seizure

Objective: About one third of partial seizures are refractory to treatment. Several anticonvulsant drugs have entered the market in recent decades but concerns about intolerance, drug interactions, and the safety of the drug are notable. One of these new anticonvulsants is pregabalin, a safe drug with almost no interaction with other antiepileptic drugs. Methods: In this open label clinical trial study, pregabalin was used for evaluation of its efficacy on reducing seizure frequency in 29 children suffering from refractory partial seizures.Average daily and weekly seizure frequency of the patients was recorded during a 6-week period (baseline period). Then, during a period of 2 weeks (titration period), pregabalin was started with a dose of 25-75 mg/d, using method of flexible dose, and was brought to maximum dose of drug that was intended in this study (450 mg/d) based on clinical response of the patients and seizure frequency. Then the patients were given the drug for 12 weeks and the average frequency of daily and weekly seizures were recorded again (treatment period). Findings : Reduction in seizure frequency in this study was 36% and the responder rate or number of patients who gained more than 50% reduction in seizure frequency was 51.7%. Conclusion: This study showed that pregabalin can be used with safety and an acceptable efficacy in treatment of childhood refractory partial seizures.Key Words: Pregabalin, Clinical trial, Refractory Partial Seizure, Seizure, Children